in just 15 patients. That definitely is nothing more than a rounding error.
the ridiculous price of the drug with minimal improvement for the few patients.
Xtandi will not get insurance coverage for its $84,000 cost after generic Zytiga hits the market later this year at less than $10,000. Generic Zytiga, which works about as well as Xtandi, is already produced in India and available on the net, by the Roswell Cancer Institute in the U.S. will soon be making it available here in a few months.
because insurance refuses to cover this ridiculously priced drug, kalydeco.
for ridiculously priced Kalydeco which cures nothing.
At 26.6 B , VRTX is supposed to be worth $1 B more than TESLA at $25.5 B. VRTX 's main drug is obsolete and its new drug which offers some relief for CF patients is too expensive to use.
While the company has lost 2/3 of its revenue base.
to stay afloat.
drugs in the pipeline. Not a $30 B company that is losing money.